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AntioxidantAbstract Phytochemical study of the aerial parts of Ficus palmata utilizing liquid–liquid fraction-
ation and different chromatographic techniques resulted in the isolation of a new isomer of psora-
lenoside namely, trans-psoralenoside (5) in addition to, one triterpene: germanicol acetate (1), two
furanocoumarins: psoralene (2), bergapten (3), one aromatic acid vanillic acid (4) and the ﬂavone
glycoside rutin (6). Structures of the isolated compounds were established through physical, 1D-
and 2D-NMR and MS data. The total extract and fractions of the plant were examined in vivo
for its possible effects as hepatoprotective, nephroprotective, antiulcer and anticoagulant activities
in comparison with standard drugs. Hepatoprotective activity was assessed via serum biochemical
parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma
glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin. Tissue parameters
such as non-protein sulfhydryl groups (NP-SH), malonaldehyde (MDA) and total protein (TP)
were also measured. In addition to tissue parameters, nephroprotective effect was evaluated by mea-
suring the serum levels of sodium, potassium, creatinine and urea. Histopathological study for both
liver and kidney cells was also conducted. Antiulcer activity was explored by observing stomach
Phytochemical and pharmacological study of Ficus palmata growing in Saudi Arabia 461lesions after treatment with ethanol. Whole blood clotting time (CT) was taken as a measure for the
anticoagulant activity of the extract. Antioxidant activity of the total extract and fractions of the
plant was measured using 2,2-diphenyl-1-picrylhydrazyl (DPPH) method and ascorbic acid as stan-
dard.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Ficus is the genus of the familyMoraceae that comprises about
800 species (Harrison, 2005). Most of the members of the fam-
ily are very high trees, shrubs and rarely herbs often with milky
juice (Hutchinson et al., 1958). There are ﬁve species of Ficus
growing in Saudi Arabia; Ficus vasta, Ficus carica, Ficus salic-
ifolia, Ficus palmata and Ficus glumosa (Migahed, 1996). A
number of Ficus species are used in folk medicine as anti-tu-
mor, anti-inﬂammatory and tonic medicament (Lansky et al.,
2008; Kitajima et al., 1999) Microbial diseases such as epilepsy
and jaundice (Noumi and Fozi, 2003; Betti, 2004), bronchitis,
inﬂuenza whooping cough, tonsillitis, toothache, bacillary dys-
entery, enteritis and bruises are also reported to be treated by
Ficus extracts. Antioxidant activities were also reported for
Ficus extracts. (Abdel-Hameed, 2009; C¸aliskan and Polat,
2011). The chemical review on genus Ficus, reveals the
presence of sterols and/or terpenes (Kuo and Li, 1997; Kuo
and Chaiang, 1999), coumarins (Chunyan et al., 2009),
furanocoumarin glycosides (Chang et al., 2005), isoﬂavones
(Li and Kuo, 1997), lignans (Li and Kuo, 2000) and chromone
(Basudan et al., 2005).
2. Materials and methods
2.1. Plant materials
The plants of F. palmate Forsk. were collected in March, 2008
from the Agabat Tanoma in the kingdom of Saudi Arabia. The
plant was identiﬁed by Dr. Mohammed Yusuf, Taxonomist of
the Medicinal, Aromatic and Poisonous Plants Research Cen-
ter (MAPPRC), College of Pharmacy, King Saud University,
Riyadh, Saudi Arabia. A voucher specimen (# 15362) has been
deposited at the herbarium of the department of Pharmacog-
nosy, College of Pharmacy, King Saud University, Riyadh,
Saudi Arabia.
2.2. General experimental procedures
Melting points were determined in open capillary tubes using
Thermosystem FP800 Mettler FP80 central processor supplied
with FP81 MBC cell apparatus, and were uncorrected. Ultra-
violet absorption spectra were obtained in methanol and with
different shift reagents on a Unicum Heyios aUV–Visible spec-
trophotometer. 1H and 13C NMR spectra were recorded on a
UltraShield Plus 500 MHz (Bruker) (NMR Unite at the Col-
lege of Pharmacy, Salman Bin Abdulaziz University) spec-
trometer operating at 500 MHz for proton and 125 MHz for
carbon, respectively. The chemical shift values are reported
in d (ppm) relative to the internal standard TMS or residual
solvent peak, the coupling constants (J) are reported in Hertz
(Hz). 2D-NMR experiments (COSY, HSQC, HMBC and
NOESY) were obtained using standard Bruker program. MSwere obtained using Liquid Chromatography/Mass Spectrom-
eter (Quattro micro API) equipped with a Z-spray electrospray
ion source (Micromass, Quattro micro, WATERS). Silica
gel 60/230–400 mesh (EM Science) and RP C-18 silica gel
40–63/230–400 mesh (Fluka) were used for column
chromatography, while silica gel 60 F254 (Merck) was used
for TLC.2.3. Extraction, fractionation and puriﬁcation
Dry leaves of Ficus palmata (1900 gm) were extracted with
95% ethanol to exhaustion and the solvent was evaporated un-
der reduced pressure using rotary vacuum evaporator to ob-
tain viscose extract. Equal volume of water was added and
the resulted extract successively partitioned with petroleum
ether (60–80 C) (3 · 500), chloroform (3 · 500), ethyl acetate
(3 · 400) and butanol (2 · 300). The solvents were evaporated
to obtain 36.9, 9.7, 8.0 and 27.5 gm of petroleum ether, chloro-
form, ethyl acetate and butanol, respectively. The left aqueous
layer was dried to give 33.4 gm.
A portion of petroleum ether layer (17.2 gm) was and chro-
matographed over silica gel column (400 gm, 5 cm i.d.). Elu-
tion the column with petroleum ether; petroleum ether:
CHCl3 (90:10–0:100) in a gradient system. On the bases of
TLC behavior, similar fractions were pooled together afford-
ing three main fractions (A–C). Fraction A (2.6 gm) was fur-
ther puriﬁed on silica gel column (50 gm, 2 cm i.d.) eluted
with petroleum ether: CHCl3 (90:10) followed by crystalliza-
tion from MeOH afforded 45 mg of 1. A similar treatment
of fraction B (3.2 gm) afforded 140 mg of b-sitosterol. Fraction
C (2.7 gm) was rechromatographed over silica gel column
eluted with petroleum ether: EtOAc mixtures in a gradient sys-
tem resulted in the isolation of 75 mg of 2 and 14 mg of 3 after
crystallization from MeOH.
Part of the chloroform layer (5 gm) was chromatographed
over silica gel column (200 gm, 3 cm i.d.) eluted with petro-
leum ether: CHCl3 (90:10) and polarity was gradually in-
creased with CHCl3 till 100% then MeOH was used in an
increasing ratio. Fractions eluted with petroleum ether: CHCl3
(85:15) (700 mg) afforded 40 mg of 2 on crystallization from
MeOH. Fraction D eluted from the column with CHCl3:-
MeOH (75:25) was subjected to reversed phase RP-18 PTLC
using MeOH:H2O (70:30) as a developing system to yield 4
(5.5 mg).
The EtOAc layer (8 gm) was chromatographed over silica
gel column. The column eluted with CHCl3:MeOH:H2O
(100:0:0–40:60:6) and then with MeOH. Fraction E eluted
from the column with CHCl3:MeOH:H2O (75:25:2.5) afforded
15 mg of 5 after crystallization from MeOH.
A portion of ButOH layer (2.5 gm) was chromatographed
on medium pressure RP-18 silica gel column started with 5%
ACN in H2O, increasing polarity with ACN afforded 6.5 mg
of compound 6.
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Wistar albino rats (150–200 g) roughly the same age
(8–10 weeks), obtained from the Experimental Animal Care
Center, College of Pharmacy, King Saud University,
Riyadh were used. The animals were housed under constant
temperature (22 ± 2 C), humidity (55%) and light/dark
conditions (12/12 h). They were provided with Purina chow
and free access to drinking water ad libitum (Abdel-Kader
et al., 2010). The experiments and procedures used in this
study were approved by the Ethics Committee of the College
of Pharmacy, King Saud University.
2.5. Chemicals
Silymarin, rutin, warfarin and 2,2-diphenyl-1-picrylhydrazyl
(DPPH) were obtained from Sigma Chemical Co., St Loui,
MO, USA. Ascorbic acid was purchased from E. Merck
(Germany).
2.6. Hepatoprotective & nephroprotective activity
Male Wistar rats were divided into ﬁfteen groups of ﬁve ani-
mals each. Group I received normal saline and was kept as a
control group. Groups II–XV received single dose of CCl4
(1.25 ml/kg body weight). Group II received only CCl4 treat-
ment. Group III was administered silymarin (Sil) at a dose of
10 mg/kg p.o. (20.7 lmole/kg) Groups IV–XIII were treated
with 100 and 200 mg/kg of the different fractions, while the
last two groups received 200 and 400 mg/kg of the total extract
respectively. Treatment started 6 days prior to CCl4 and con-
tinued till day seven. After 24 h, following CCl4 administration
in day 7 the animals were sacriﬁced using ether anesthesia.
Blood samples were collected by heart puncture and the serum
was separated for evaluating the biochemical parameters.
2.7. Determination of AST, ALT, GGT, ALP, bilirubin,
creatinine, urea, potassium and sodium levels
The biochemical parameters such as aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), gamma glutamyl
transpeptidase (GGT), alkaline phosphatase (ALP) and total
bilirubin were estimated by reported methods (Edwards and
Bouchier, 1991). The enzyme activities were measured using
diagnostic strips (Reﬂotron, ROCHE) and were read on a
Reﬂotron Plus instrument (ROCHE). Serum creatinine and
blood urea were assayed using Randox Diagnostic kits
(Randox Laboratories Ltd., Crumlin, U.K.) by the reported
method (Varley and Alan,1984). Potassium level was measured
using diagnostic strips (Reﬂotron, ROCHE) while photomet-
ric determination of sodium level was done using Mg-urany-
lacetate method (Henry et al., 1974).
2.8. Determination of non-protein sulfhydryl groups (NP-SH),
malonaldehyde (MDA) and total protein (TP)
The liver and kidney samples were separately cooled in a bea-
ker immersed in an ice bath. The tissues were homogenized in
0.02 M ethylenediaminetetraacetic acid (EDTA) in a Potter–
Elvehjem type C homogenizer. Homogenate equivalents of100 mg tissues were used for the measurements. Non-protein
sulfhydryl groups (NP-SH) were quantiﬁed by mixing homo-
genated with 4 ml of distilled water and 1 ml of 50% trichloro-
acetic acid (TCA) in 15 ml test tubes. The tubes were shaken
intermittently for 10–15 min and centrifuged for 15 min at
approximately 3000 rpm to precipitate the protein. 2 ml of
the supernatant was mixed with 4 ml of 0.4 M Tris buffer,
pH 8.9 and 0.1 ml of 0.01 M DTNB [5,50-dithio-bis-(2-nitro-
benzoic acid)] and the samples were shaken. The absorbance
was measured spectrophotometrically within 5 min of addition
of DTNB at 412 nm against a reagent blank with no homoge-
nate (Sedlak and Lindsay, 1968).
For the level of MDA aliquots of homogenate were incu-
bated at 37 C for 3 h in a metabolic shaker. Then 1 ml of
10% aqueous TCA was added and mixed. The mixture was
then centrifuged at 800 rpm for 10 min. One milliliter of the
supernatant was removed and mixed with 1 ml of 0.67% w-
thiobarbituric acid in water and placed in a boiling water bath
for 10 min. The mixture was cooled and diluted with 1 ml dis-
tilled water. The absorbance of the solution was then measured
at 535 nm. The content of MDA (nmol/g wet tissue)(index of
the magnitude of lipid peroxidation) was then calculated, by
reference to a standard curve of MDA solution (Utley et al.,
1967).
For TP determination parts of the homogenate were treated
with 0.7 ml of Lowry’s solution, mixed and incubated for
20 min in dark at room temperature. Diluted Folin’s reagent
(01 ml) was then added and samples were incubated at room
temperature in dark for 30 min. The absorbance of the resulted
solutions was then measured at 750 nm (Lowry et al., 1951).
2.9. Histopathology
The ﬁxed liver and kidney samples were placed in cassettes and
loaded into tissue baskets. They were subjected to dehydration,
clearing and inﬁltration by immersion in different concentra-
tions of ethanol (70–100%), xylene (3 times, 1 h each) and ﬁ-
nally parafﬁn wax (4 times, 1 h each). The tissues were then
transferred into molds ﬁlled with parafﬁn wax. After orienting,
the tissues by hot forceps the molds were chilled on cold plates
and excess wax were trimmed off using a knife. The rotary
microtome (Leitz 1512) was used for making thin sections
(3 lm). The sections were placed onto clean slides that were
drained vertically for several minutes before placing them onto
a warming table at 37–40 C (Prophet et al., 1994). The slides
were then deparafﬁnized, hydrated and stained in Mayer’s
hematoxylin solution for 15 min. The slides were then washed
in lukewarm running tap water for 15 min and placed in dis-
tilled water. After they were immersed in 80% ethyl alcohol
for one to two minutes they were counterstained in eosin-
phloxine solution for 2 min. The slides were then dehydrated
and cleared through two changes each of 95% ethyl alcohol,
absolute ethyl alcohol, and xylene (2 min each) and ﬁnally
mounting with resinous medium.
2.10. Antiulcer activity
Rats were divided into thirteen groups of 5 animals each. All
animals received 1 ml 80% ethanol. Group I served as positive
control. Groups II–XI were treated with 100 and 200 mg/kg of
different fractions, while groups XII and XIII received 200 and
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of ethanol. One hour after the administration of ethanol, rats
were scariﬁed and examined for stomach lesions. Patchy le-
sions of the stomach induced by ethanol were scored according
to the method described by Robert et al. (1983).2.11. Determination of whole blood clotting time (CT)
Clotting time was determined according to the reported meth-
od (Dacie and Lewis, 1968). Rats were divided into thirteen
groups of 5 animals each. Group I received 10 mg/kg of war-
farin and served as positive control. Groups II–XI were treated
with 100 and 200 mg/kg of different fractions, while groups
XII and XIII received 200 and 400 mg/kg of the total extract.
0.4 ml of blood samples were collected at 0, 30, 60, 120 min
from the retrorbital sinus venous channels. The blood samples
were dispensed separately into prewarmed test tubes ﬁxed in a
rack previously placed in a water bath maintained at 37 C.
Tubes were tilted to check for the sign of blood clot every
30 s. Using a stopwatch, the time interval between blood col-
lection and the time the clot appearing in each test tube was
recorded in min.2.12. In vitro antioxidant activity using DPPH radical
scavenging assay
The method was carried out as described by Brand et al.
(1995). Various concentrations (10, 50, 100, 500 and 1000 lg/
ml) of the crude extract and fractions were used. The assay
mixtures contained in total volume of 1 ml, 500 lL of the ex-
tract, 125 lL prepared DPPH and 375 lL solvent. Ascorbic
acid was used as the positive control. After 30 min incubation
at 25 C, the decrease in absorbance was measured atFig. 1 Histopathological appearance of Liver cells; (L-1) normal cel
activation, cytoplasmic vacuolization of hepatocytee and focal hepatic
cells of rats treated with CCl4 and Sil small focal hepatic necroses with
cells; (L-4) liver cells of rats treated with CCl4 and 400 mg/kg total ext
changes; (L-5) liver cells of rats treated with CCl4 and 200 mg/kg total
(L-6) (L-7) liver cells treated with 100 and 200 mg/kg of the petroleum
histopathological changes; (L-8) liver cells treated with 200 mg/kg chlo
only slight hydropic degeneration.k= 517 nm. The radical scavenging activity was calculated
from the equation:
% radical scavenging activity
¼ ððA controlA sampleÞ=A controlÞ  100
2.13. Statistical analyses
For each set of experiments where two or more than two
groups were compared, an analysis of variance (ANOVA) test
was used to determine the signiﬁcance of the differences. Dif-
ferences between the control and CCl4-treated group were
compared for signiﬁcance using Dunnette test for non paired
samples (Woolson and Clarke, 2002). All the values shown
are the mean ± S.E.3. Results
Phytochemical study of the aerial parts of F. palmata resulted
in the isolation of two furanocoumarin derivatives, rutin, ger-
manicol acetate, vanillic acid and psoralenoside methyl ether.
The structures of the compounds are presented in Fig. 1.
The total extract and different fractions were tested for hepa-
toprotective and nephroprotective effect against CCl4 induced
toxicity. The results are presented in Tables 1–3. Antiulcer po-
tential of the extract and fractions was also explored against
ethanol-induced lesions. Results are presented in Table 4.
The results of anticoagulant effect in comparison with warfa-
rin based on whole blood clotting time (CT) are presented in
Table 5. Total extract and fractions were tested for their anti-
oxidant activity using DPPH radical scavenging assay. Results
of this study are presented in Table 6.ls; (L-2) liver cells of rats treated with CCl4 showed Kupffer cells
necrosis associated with inﬂammatory cells inﬁltration; (L-3) liver
few inﬂammatory cells inﬁltration and slight activation of kupffer
ract showing excellent recovery with absences of histopathological
extract showing slight hydropic degeneration of some hepatocytes;
ether fraction resulted in complete protection and absence of any
roform fraction showing moderate protection of hepatocytes with
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3.1.1. Germanicol acetate (1)
C32H52O2; White crystals; mp 279–280 C; 1H NMR
(500 MHz, CDCl3): dH 0.73 (3H,s, H-27), 0.84 (3H,s, H-24),
0.85 (3H,s, H-23), 0.91 (3H,s, H-26), 0.93 (3H,s, H-29), 0.94
(3H,s, H-30), 1.02 (3H,s, H-28), 1.08 (3H,s, H-25), 2.05 (3H,
s, CH3-CO), 4.49 (1H, dd, J= 11.5, 6.2 Hz, H-3a), 4.80
(1H, s, H-19); 13C NMR (125 MHz, CDCl3): dC 14.6 (C-27),
16.1 (C-25), 16.5 (C-24), 16.8 (C-26), 18.2 (C-6), 21.1 (C-11),
21.3 (CO-CH3), 23.7 (C-2), 25.3 (C-28), 26.2 (C-12), 27.5 (C-
15), 27.9 (C-23), 29.2 (C-30), 31.4 (C-29), 32.4 (C-20), 33.3
(C-21), 34.4 (C-17), 34.5 (C-7), 37.2 (C-22), 37.4 (C-16), 37.8
(C10), 38.4 (C-4), 38.5 (C-1), 38.6 (C-13), 40.8 (C-8), 43.3
(C-14), 51.1 (C-9), 55.6 (C-5), 81.0 (C-3), 129.8 (C-19), 142.7
(C-18), 171.1 (CO-CH3); ESIMS m/z 491 (19, [M + Na]
+),
469 (100, [M + H]+).
3.1.2. Psoralene (2)
C11H6O3; Colorless crystals; mp 162–163 C; UV kmax
(MeOH): 240, 245, 292, 327; 1H NMR (500 MHz, CDCl3):
dH 6.40 (d, J= 9.5 Hz, H-3), 7.49 (s, H-8), 7.50 (d,
J= 1.5 Hz, H-30), 7.71 (s, H-5), 7.72 (d, J= 1.5 Hz, H-20),
7.82 (d, J= 9.5 Hz, H-4); 13C NMR (125 MHz, CDCl3): dC
99.88 (C-8), 106.39 (C-30), 114.66 (C-3), 115.42 (C-10),
119.85 (C-5), 124.88 (C-6), 144.10 (C-4), 146.92 (C-20),
152.04 (C-9), 156.42 (C-7), 161.04 (C-2); ESIMS m/z 209 (33,
[M +Na]+), 187 (100, [M +H]+).
3.1.3. Bergapten (5-Methoxypsoralen) (3)
C12H8O4; White powder; mp191–192 C; UV kmax (MeOH):
221, 248, 260, 269, 311; 1H NMR (500 MHz, CDCl3): dH
6.29 (d, J= 9.5 Hz, H-3), 7.15 (s, H-8), 7.04 (d, J= 1.5 Hz,
H-30), 7.61 (d, J= 1.5 Hz, H-20), 8.17 (d, J= 9.5 Hz, H-4);
13C NMR (125 MHz, CDCl3): dC 60.09 (OCH3), 93.82 (C-8),
105.06 (C-30), 105.06 (C-10), 112.53 (C-3), 112.66 (C-6),
139.29 (C-4), 144.80 (C-20), 149.58 (C-9), 152.70 (C-5),
158.38 (C-7), 161.26 (C-2); ESIMS m/z 239 (24,
[M +Na]+), 217 (100, [M +H]+).
3.1.4. Vanillic acid (4)
C8H8O4; White powder; mp 210–211 C; UV kmax (MeOH):
258, 292; 1H NMR (500 MHz, DMSO-d6): dH 3.81 (3H, s,
OCH3), 6.85 (1H, d, J= 8 Hz, H-5), 7.47 (1H, d, J= 2 Hz,
H-2), 7.52 (1H, dd, J= 8, 2 Hz, H-6); 13C NMR (125 MHz,
DMSO-d6): dC 55.42 (OCH3), 112.64 (C-2), 114.99 (C-5),
121.76 (C-1), 123.47 (C-6), 147.14 (C-3), 150.99 (C-4), 167.37
(C‚O); ESIMS m/z 191 (42, [M +Na]+), 169 (100,
[M +H]+).
3.1.5. Psoralenoside (5)
C17H18O9; White powder; mp 253 C; UV kmax (MeOH):
244, 285, 324; 1H NMR (500 MHz, CD3OD): dH 3.45
(m, H-400), 3.53 (m, H-300), 3.53 (m, H-500), 3.61 (t, J= 8 Hz,
H-200), 3.68 (dd, J= 5.5, 10.5 Hz, H-600), 3.95 (bd,
J= 10.5 Hz, H-600), 5.03 (d, J= 8.25 Hz, H-100), 6.57 (d,
J= 16.5 Hz, H-3), 6.84 (d, J= 2 Hz, H-3’), 7.46 (s, H-8),
7.74 (d, J= 2 Hz, H-20), 7.93 (s, H-5), 8.20 (d, J= 16.5 Hz,
H-4); 13C NMR (125 MHz, CD3OD): dC 61.02 (C-600), 69.81
(C-400), 73.38 (C-200), 76.59 (C-300), 76.81 (C-500), 98.76 (C-8),101.78 (C-100), 106.01 (C-30), 117.27 (C-10), 119.27 (C-3),
120.58 (C-6), 122.45 (C-5), 140.37 (C-4), 145.64 (C-20),
154.27 (C-9), 156.75 (C-7), 176.50 (C-2); ESIMS m/z 389 (18,
[M+ Na]+), 367 (100, [M+ H]+).
4. Discussion
Phytochemical investigation of the aerial parts of Ficus pal-
mata resulted in the isolation of 6 compounds germanicol ace-
tate (1) (Gonza`lez et al., 1981; Dat et al., 2002), psoralene (2)
(O’Neil, 2001; Abu-Mustafa and Fayez, 1967), bergapten (5-
methoxypsoralen) (3), vanillic acid (4) (Pouchert and Behnke,
1992) and the ﬂavone glycoside rutin (6) (Bilia et al., 1996)
which were identiﬁed by a comparison of their physical and
spectral data with literature as well as direct comparison with
authentic material whenever available.
13C NMR showed signals for 6 oxygenated carbons from dC
61.02 to 76.81 and 101.78 ppm and their correlated protons
from dH 3.45 to 5.03 ppm in the
1H NMR assigned for b-D-
glucopyranoside (experimental) indicating the glycosidic nature
of 5. The aglycone part showed 11 carbon signals and 6 protons.
The signals were comparable to those of 2 with some signiﬁcant
differences. As 2 have no free OH for glycosilation one should
expect a ring opening to obtain 5. C-2 in 5 showed signal at
dC 176.50 while the same signal in 2 appeared at dC
161.04 ppm (experimental) indicating a ring opening of the a-
pyrone ring in 5 and conversion of C-2 into carboxylic group.
The resulting hydroxyl at C-9 consequently is the site of connec-
tion of glucose. This fact was proved undoubtedly from the re-
sults of an HMBC experiment where the H-100 proton signal of
glucose at dH 5.03 ppm showed correlation with the C-9 carbon
at dC 154.27 ppm. A closely related compound was isolated
from Psoralea cotylifolia and named psoralenoside (Qiao
et al., 2006). The major difference between psoralenoside and
5 is the orientation around C-3, C-4 double bond. In case
psoralenoside the J3,4 = 12.4 Hz (Qiao et al., 2006) indicates
a cis-orientation of the two protons, however, that value in 5
is 16.5 Hz (experimental) clearly indicates a trans-orientation
between H-3 and H-4. From the above discussion 5 was
identiﬁed as a new isomer of psoralenoside and the name
trans- psoralenoside was proposed to differentiate from the
known cis isomer.
4.1. Serum parameters related to hepatoprotective activity
Hepatic toxicity following CCl4 administration is reﬂected by
increase in the biochemical parameter levels such as aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma glutamyl transpeptidase (GGT), alkaline phosphatase
(ALP), and total bilirubin (Table 1) (Edwards and Bouchier,
1991). Pretreatment of rats with Sil, signiﬁcantly (p< 0.001)
decreased the raised levels of AST, ALT, GGT, ALP and bil-
irubin induced by CCl4 (42.30, 67.77, 53.84, 32.08 and 64.55%
respectively) (Table 1) indicating a good recovery from the
hepatotoxic agent. Treatment with F. palmata total extract
showed dose dependent reduction in the levels of all the mea-
sured parameters. Animal treated with 400 mg/kg body weight
of F. palmata showed a signiﬁcant (p< 0.01–p< 0.001)
reduction in the levels of AST, ALT, GGT, ALP and bilirubin
(27.36, 39.85, 29.72, 20.69, and 51.61%) indicating good pro-
tection against liver damage induced by CCl4. Treatment with
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Phytochemical and pharmacological study of Ficus palmata growing in Saudi Arabia 465200 mg/kg body weight resulted in less improvement in the
parameters, However, all the results were highly signiﬁcant
(p< 0.01–p< 0.001) except reduction in ALP (15.94%,
p< 0.05) (Table 1).
All fractions were tested for hepatoprotective effect at 100
and 200 mg/kg body weight. The best protective effect was ob-
tained with petroleum ether and chloroform fractions. 200 mg/kg
body weight of the petroleum ether showed better results than
200 mg/kg body weight of the total extract in reducing the ele-
vated levels of ALT, GGT, ALP and bilirubin. The higher
dose of the chloroform fractions was better than the total ex-
tract in lowering the levels of AST, GGT and ALP (Table 1).
The water layer at 200 mg/kg body weight showed some
activity while the ethyl acetate and butanol were almost
inactive (Table 1).
4.2. Serum parameters related to nephroprotective activity
The Kidney regulates plasma ionic composition including so-
dium, potassium, calcium, magnesium, chloride. It is also con-
cerned with the removal of nitrogenous metabolic waste
products such as urea, creatinine and uric acid (Pocock and
Richards, 2006). Elevations of serum electrolytes, urea and cre-
atinine are considered reliable parameters for investigating
drug-induced nephrotoxicity in animals and man (Adelman
et al., 1981). CCl4 exhibits a signiﬁcant rise in the biochemical
markers of kidney functions like serum urea, serum creatinine,
sodium and potassium levels (Table 2). Pretreatment with Sil
(10 mg/kg p.o) decreased the raised levels of serum urea, serum
creatinine, percentage of sodium and potassium (34.33, 25.75,
49.77 and 67.23%) induced by CCl4 (Table 2). Dose dependent
reduction in the elevated parameters resulted from the treat-
ment with F. palmata total extract. Animals treated with
400 mg/kg body weight of F. palmata showed highly signiﬁcant
(p< 0.01–p< 0.001) reduction in the levels of serum urea, ser-
um creatinine, sodium and potassium levels (50.56, 34.28, 28.94
and 45.19%) indicating a good protection against CCl4
induced nephrotoxicity. Reduction in the levels of serum urea
and serum creatinine was more than that resulted from the
treatment with the standard drug Sil. Treatment with
200 mg/kg body weight resulted in less protection than the
higher dose and signiﬁcance ranged from p< 0.01–p< 0.01.
Reduction in the levels of serum urea was more than that
resulted from treatment with the standard drug Sil (Table 2).
At 100 mg/kg dose the petroleum ether fraction improved
all the measured parameters with values slightly better than
those resulted from pretreatment with total extract at
200 mg/kg body weight. Similarly, the chloroform fraction
at the higher dose improved the levels of urea, creatinin, so-
dium and potassium (30.32, 37.28, 29.13 and 46.98% respec-
tively). However, the 100 mg/kg body weight was less
effective than the lower dose of the total extract except in
the level of potassium that was reduced by 42.26%. The ef-
fect of the other fractions was very weak and statistically
insigniﬁcant (Table 2).
4.3. Tissue parameters related to both hepatoprotective and
nephroprotective
Glutathione-S-transferases (GSTs) catalyze the transfer of re-
duced glutathione (GSH) to reactive electrophiles, a function
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466 S.I. Alqasoumi et al.that serves to protect cellular macromolecules from interaction
with electrophiles that contain electrophilic heteroatoms
(–O, –N, and –S) and in turn protects the cellular environment
from damage. Severe reduction in GSH content can predispose
cells to oxidative damage, a state that is linked to a number of
human health issues (Brunton et al., 2006).
Treatment of animals with CCl4 at a dose of 400 mg/kg de-
creased the hepatic and renal NP-SH from 5.55 ± 0.33,
11.86 ± 0.86 to 1.18 ± 0.17, 3.48 ± 0.58 lmol/gm wet weight
tissue, respectively (Table 3). Pretreatment of the animals with
Sil at a dose of 10 mg/kg signiﬁcantly increased the reduced
NP-SH content (p< 0.01, P< 0.001) to 4.34 ± 0.34 and
6.65 ± 0.43 lmol/gm wet weight tissue in hepatic and renal tis-
sues respectively. Animals that received the total extract of F.
palmata showed a signiﬁcant dose dependent recovery of the
NP-SH contents. Pre-treatment with 400 mg/kg F. palmata to-
tal extract signiﬁcantly increased the reduced content of NP-
SH in the liver and kidney tissues to 2.46 ± 0.22 and
8.23 ± 0.69 lmol/gm wet weight tissues respectively
(p< 0.01). The 200 mg/kg dose was less effective but statisti-
cally signiﬁcant (p< 0.05). The NP-SH contents in the liver
and kidney tissues were increased to 1.96 ± 0.12 and
7.22 ± 0.78 lmol/gm wet weight tissues respectively. Restor-
ing the NP-SH content in the kidney tissue exceeded that
caused by Sil (Table 3). Treatment with the petroleum ether
fraction at 200 and 100 mg/kg resulted in a highly signiﬁcant
improvement in the liver contents of NP-SH (4.55 ± 0.49
and 4.50 ± 0.46 lmol/gm wet weight tissue, respectively) com-
parable to that caused by Sil. Regarding the kidney contents of
NP-SH the higher dose of the petroleum ether fraction re-
stored the NP-SH contents to 8.96 ± 0.35 lmol/gm wet weight
tissue exceeding the improvement resulted from treatment of
the total extract and Sil The results were highly signiﬁcant.
The chloroform fraction at 200 mg/kg resulted in a highly sig-
niﬁcant best improvement in the NP-SH contents in this study
(9.29 ± 0.21 lmol/gm wet weight tissue). The effect of the
ethyl acetate fraction at the two doses used was comparable
to that of the lower dose of the extract (Table 3).
Malonaldehyde (MDA) is the main end-product of polyun-
saturated fatty acid peroxidation (PUFA) following Reactive
oxygen species (ROS) insult (Esterbauer et al., 1991). MDA
is a reactive aldehyde and is one of many reactive electrophile
species that cause toxic stress in cells and form covalent protein
adducts (Farmer and Davoine, 2007). The production of this
aldehyde is used as a biomarker to measure the level of oxida-
tive stress in an organism (Del Rio et al., 2005). Normal con-
trol group showed 1.07 ± 0.08 and 1.60 ± 0.08 nmol/l
concentrations of MDA in their healthy liver and kidney tis-
sues respectively. The levels of MDA greatly increased after
CCl4 treatment to 4.060 ± 0.47 and 6.15 ± 0.25 nmol/l in liver
and kidney tissues respectively. The standard drug Sil was
effective in reducing these elevated levels to 2.87 ± 0.43 and
3.44 ± 0.20 nmol/l in liver and kidney tissues respectively. F.
palmata total extract resulted in a dose dependent reduction
in the MDA levels. Treatment of the animals with 400 mg/kg
body weight decreased the level of MDA to 2.54 ± 0.22 nmol/
l (p< 0.01) in liver tissues and 3.74 ± 0.23 nmol/l (p< 0.001)
in kidney tissues reﬂecting the level of protection similar to
that of Sil (Table 3). Both petroleum ether and chloroform
fractions at the 200 mg/kg resulted in a highly signiﬁcant
(p< 0.001 and p< 0.01, respectively) decrease in the
level of MDA in liver tissues to 1.49 ± 0.10 and
Table 3 Effect of F. palmata total extract and fractions on NP-SH, MDA and TP in rat liver and kidney.
Treatment (n= 5) Dose (mg/kg) NP-SH (nmol/l) MDA (nmol/l) Protein (g/l)
Liver Kidney Liver Kidney Liver Kidney
Normal 5.55 ± 0.33 11.86 ± 0.86 1.07 ± 0.08 1.60 ± 0.08 129.03 ± 6.05 81.93 ± 3.22
CCl4 1.25 ml/kg 1.18 ± 0.17*** 3.48 ± 0.58
*** 4.60 ± 0.47*** 6.15 ± 0.25*** 57.41 ± 3.22*** 35.48 ± 1.93***
Sily. +CCl4 10 4.34 ± 0.34
*** 6.65 ± 0.43** 2.87 ± 0.43* 3.44 ± 0.20*** 74.83 ± 8.09 57.41 ± 3.22**
Total 200 1.96 ± 0.12* 7.22 ± 0.78* 2.54 ± 0.22** 3.74 ± 0.23*** 80.00 ± 4.82** 51.61 ± 4.08*
Total 400 2.46 ± 0.22** 8.23 ± 0.69** 1.99 ± 0.12** 2.56 ± 0.26*** 96.12 ± 6.44** 62.58 ± 4.51**
Pet. ether 100 4.50 ± 0.46*** 6.95 ± 0.50** 2.02 ± 0.25** 2.94 ± 0.23*** 90.96 ± 8.04** 59.35 ± 4.08**
Pet. ether 200 4.55 ± 0.49*** 8.96 ± 0.35*** 1.49 ± 0.10*** 2.08 ± 0.16*** 110.96 ± 4.08*** 72.25 ± 2.78***
CHCl3 100 2.94 ± 0.40
** 7.48 ± 0.94* 2.41 ± 0.10** 3.42 ± 0.46** 79.35 ± 3.99** 52.25 ± 5.20*
CHCl3 200 3.24 ± 0.34
** 9.29 ± 0.21*** 1.95 ± 0.18** 2.60 ± 0.23** 90.96 ± 6.35** 67.09 ± 4.08***
EtOAc 100 1.64 ± 0.13 7.38 ± 0.465** 4.74 ± 0.31 5.69 ± 0.51 52.90 ± 3.41 36.77 ± 2.86
EtOAc 200 1.57 ± 0.10 7.60 ± 0.83* 4.52 ± 0.34 4.88 ± 0.15** 56.12 ± 6.77 40.00 ± 2.68
n-Butanol 100 1.31 ± 0.28 3.07 ± 0.39 3.91 ± 0.32 3.82 ± 0.26*** 65.16 ± 4.26 52.25 ± 2.86**
n-Butanol 200 1.27 ± 0.17 2.41 ± 0.32 4.00 ± 0.37 3.27 ± 0.06*** 62.58 ± 6.61 60.64 ± 3.07***
Water 100 1.03 ± 0.06 3.70 ± 0.94 3.14 ± 0.14* 4.83 ± 0.41* 74.83 ± 2.78** 45.80 ± 2.86*
Water 200 1.38 ± 0.13 2.89 ± 0.35 2.81 ± 0.22* 4.38 ± 0.41= 79.35 ± 5.20* 49.67 ± 3.85*
* p< 0.05.
** p< 0.01.
*** p< 0.001.
Table 4 Effect of F. palmata total extract and fractions on the
gastric lesion induced by 80% ethanol.
Treatments Dose (mg/kg) Ulcer index (Mean ± S.E.)
Ethanol 80% 1 ml 8.00 ± 0.57
Total ext. + ethanol 80% 200 4.00 ± 0.57**
Total ext. + ethanol 80% 400 2.00 ± 0.57***
Pet. ether + ethanol 80% 100 5.00 ± 0.57**
Pet. ether + ethanol 80% 200 3.33 ± 0.33**
CHCl3 + ethanol 80% 100 6.33 ± 0.66
CHCl3 + ethanol 80% 200 4.00 ± 0.57
**
EtoAC+ ethanol 80% 100 7.66 ± 0.33
EtoAC+ ethanol 80% 200 6.66 ± 0.66
n-Butanol + ethanol 80% 100 8.00 ± 0.57
n-Butanol + ethanol 80% 200 7.33 ± 0.66
Water + ethanol 80% 100 7.66 ± 0.88
Water + ethanol 80% 200 6.00 ± 0.57*
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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two fractions was observed in the kidney tissues where the
MDA contents were reduced to 2.08 ± 0.16 and
2.60 ± 0.23 nmol/l. The resulted improvement exceeded that
resulted from pretreatment with the standard drug Sil in the li-
ver and kidney tissues (2.87 ± 0.43 and 3.44 ± 0.20 nmol/l,
respectively) (Table 3).
One of the most important liver functions is protein synthe-
sis. Liver damage causes disruption and disassociation of pol-
yribosomes on the endoplasmic reticulum thereby reducing the
biosynthesis of protein. The TP levels depressed in hepatotoxic
conditions due to defective protein biosynthesis. Restoring the
normal levels of TP is an important parameter for liver recov-
ery (Navarro and Senior, 2006). Treatment of rats with CCl4
resulted in a more than 50% reduction in liver and kidney tis-
sue protein contents (Table 3). Treatment with Sil increased
the levels of TP in both liver and kidney tissues to
74.83 ± 8.09 g/l and 57.41 ± 3.22 g/l respectively. Highlysigniﬁcant results (p< 0.01) resulted from the treatment with
400 mg/kg body weight F. palmata total extract. The TP levels
increased in liver tissues to 96.12 ± 6.44 g/l and in kidney tis-
sues to 62.58 ± 4.51 g/l respectively. These results indicated
that the extract has more protection at this dose than Sil.
Traetment with 200 mg/kg body weight F. palmata total ex-
tract increased levels of proteins to 80.00 ± 4.82 and
51.61 ± 4.08 in liver and kidney tissues respectively. Both
petroleum ether and chloroform fractions at the 200 mg/kg re-
sulted in a highly signiﬁcant (p< 0.001 and p< 0.01) increase
in the TP levels in liver tissues (110.96 ± 4.08 and
90.96 ± 6.35 g/l) and kidney tissues (72.25 ± 2.78 and
67.09 ± 4.08 g/l) respectively. These results are better than
the improvement caused by Sil and total extract (Table 3).
4.4. Histopathological study
The histological appearance of the liver and kidney cells re-
ﬂects their conditions (Prophet et al., 1994). The histopathol-
ogy of the normal hepatic cells is presented in Fig. 1, L-1.
Treatment with CCl4 resulted in Kupffer cells’ activation,
cytoplasmic vacuolization of hepatocytee and focal hepatic
necrosis associated with inﬂammatory cells’ inﬁltration.
(Fig. 1, L-2). Liver samples of rats treated with Sil prior
CCl4 administration showed small focal hepatic necroses with
few inﬂammatory cells’ inﬁltration and slight activation of
kupffer cells (Fig. 1, L-3). Treatment with 400 mg/kg body
weight F. palmata total extract showed excellent recovery with
absences of histopathological changes (Fig. 1, L-4). The liver
cells of rats treated with the lower dose of the total extract
(200 mg/kg body weight) showed slight hydropic degeneration
of some hepatocytes (Fig. 1, L-5). Pretreatment with 100 and
200 mg/kg body weight of the petroleum ether fraction re-
sulted in complete protection and absence of any histopathol-
ogical changes (Fig. 1, L-6 and L-7). The chloroform fraction
at doses of 200 mg/kg body weight showed moderate protec-
tion of hepatocytes with only slight hydropic degeneration
(Fig. 1, L-8).
Table 5 Effect of F. palmata total extract and fractions on clotting time.
Treatment (n= 5) Dose (mg/kg) 0 min 30 min 60 min 120 min
Norma saline 1 ml 2.46 ± 0.14 2.8 ± 0.05 2.46 ± 0.08 2.63 ± 0.08
Warfarin 10 2.60 ± 0.05 5.70 ± 0.32*** 7.83 ± 0.63*** 8.23 ± 0.67***
Total 200 2.33 ± 0.17 4.23 ± 0.37** 5.46 ± 0.38*** 6.16 ± 0.24***
Total 400 2.83 ± 0.17 5.20 ± 0.26*** 6.00 ± 0.43** 6.70 ± 0.26***
Pet. ether 100 2.66 ± 0.12 2.80 ± 0.05 4.06 ± 0.31** 5.70 ± 0.32***
Pet. ether 200 2.83 ± 0.17 4.53 ± 0.38** 5.63 ± 0.56** 5.70 ± 0.32***
CHCl3 100 2.83 ± 0.17 5.10 ± 0.34
** 4.93 ± 0.20*** 5.03 ± 0.24***
CHCl3 200 2.36 ± 0.24 3.10 ± 0.34 4.60 ± 0.26
** 5.10 ± 0.25***
EtOAc 100 3.06 ± 0.08 3.23 ± 0.43 3.13 ± 0.17 3.30 ± 0.25
EtOAc 200 2.86 ± 0.20 3.36 ± 0.35 2.83 ± 0.17 3.50 ± 0.37
n-Butanol 100 2.56 ± 0.35 2.96 ± 0.32 3.23 ± 0.20 3.60 ± 0.26
n-Butanol 200 2.56 ± 0.40 3.60 ± 0.47 4.33 ± 0.40* 4.60 ± 0.26**
Water 100 3.03 ± 0.27 5.03 ± 0.17** 5.23 ± 0.23** 4.93 ± 0.58*
Water 200 3.03 ± 0.24 4.00 ± 0.36 5.03 ± 0.17** 5.70 ± 0.32**
* p< 0.05.
** p< 0.01.
*** p< 0.001.
Table 6 Free radical-scavenging activity (DPPH-assay).
Treatment Radical scavenging activity (%)
10 50 100 500 1000
Total ext. 26.1 27.0 40.9 93.8 94.5
Pet. ether 2.7 7.8 11.7 22.8 47.8
CHCl3 6.0 22.1 48.1 92.3 92.1
EtOAc 30.2 80.9 97.3 97.0 96.5
n-butanol 8.9 11.4 37.0 83.0 92.5
Water 11.1 18.8 23.2 28.3 50.8
Ascorbic acid (STD) 41.0 86.4 95.5 98.1 98.3
468 S.I. Alqasoumi et al.Histopathological study revealed the normal renal architec-
ture in control group (Fig. 2, K-1). Kidney cells of rats treated
with CCl4 showed dramatic histopathological changes appear-
ing as cytoplasmic vaculation, vacular degeneration of epithe-
lial lining renal tubules, focal inﬂammatory cells inﬁltration
and preivascular edema (Fig. 2, K-2). Pretreatment with Sil re-
sulted in good protection indicated by slight vacuolation of
epithelial lining renal tubules and endothelial lining glomerular
tuft (Fig. 2, K-3). Renal cells of rats treated with CCl4 and 400
or 200 mg/kg body weight F. palmata total extract showed
complete recovery of renal cells with no histopathological
changes (Fig. 2, K-4 and K-5). kidney cells of rats treated with
CCl4 and 200 mg/kg of the petroleum ether fraction showed
complete recovery as no histopathological changes were ob-
served (Fig. 2, K-6), while cells of rats treated with 100 mg/
kg of the petroleum ether fraction showed slight vaculations
of epithelial lining of some renal tubules (Fig. 2, K-7). Treat-
ment with CCl4 and 200 mg/kg of the chloroform fraction
showed complete recovery as no histopathological changes
were observed (Fig. 2, K-8).
4.5. Antiulcer activity
Peptic ulcer is one of the most common, chronic gastrointesti-
nal disorders. It has become a common global health problem
affecting a large number of people worldwide and still a majorcause of morbidity and mortality (Chan and Leung, 2002). In-
ﬂamed lesions or excavations of the mucosa and tissue that
protect the gastrointestinal tract characterize peptic ulcer.
Damage of mucus membrane that normally protects the
esophagus, stomach and duodenum from gastric acid and pep-
sin causes peptic ulcer (Brenner and Stevens, 2006). Many
plants showed good antiulcer activity such as Jasminum gran-
diﬂorum, Anogeissus latifolia, Solanum nigrum, Azadirachta
indica and Ocimum sanctum (Sen et al., 2009; Kumar et al.,
2011). F. palmata total extract was tested at 200 and 400 mg/kg
body weight for possible antiulcer effect against 80% ethanol
induced lesions. All the fractions were tested at two doses of
100 and 200 of mg/kg body weight. The ulcer index of the
group treated with 80% ethanol was 8.00 ± 0.57 (Table 4).
Protection against ulcer by F. palmata total extract was dose
dependent and highly statistically signiﬁcant (p < 0.01–
p < 0.001). The best protection was observed with the higher
dose of the total extract where ulcer index is 2.00 ± 0.57
(Table 4). Good protection also resulted from treatment with
petroleum ether and chloroform fraction with ulcer indexes
of 3.33 ± 0.33 and 4.00 ± 0.57 respectively (Table 4).
4.6. Determination of whole blood clotting time (CT)
Coumarins and coumarin derivatives are well known for their
anticoagulant effect (Murray et al., 1982; Penning-van Beest
et al., 2005). F. palmata total extract and all fractions were sub-
jected to CT assay using warfarin as standard. The increase in
the CT resulted from treatment with total extract, petroleum
ether and chloroform fractions was statistically signiﬁcant,
time dependent and dose dependent. The total extract at a dose
of 400 mg/kg body weight resulting in an increase in CT
reached 6.70 ± 0.26 while warfarin time was 8.23 ± 0.67 after
120 min. The effect of the 200 mg/kg body weight was very
close to that of the high dose after 120 min although it was less
at the early stages of the experiment. The petroleum ether frac-
tion ended up with the same efﬁcacy after 120 min; however,
the higher dose (200 mg/kg) was more effective after 30 and
60 min. The chloroform fraction was the second effective
among the fractions. At the 200 mg/kg dose the chloroform
fraction increased the CT to 5.10 ± 0.25 after 120 min.
Fig. 2 Histopathological appearance of kidney cells; (K-1) normal cells; (K-2) kidney cells of rats treated with CCl4 cytoplasmic
vaculation, vacular degeneration of epithelial lining renal tubules, focal inﬂammatory cells inﬁltration and preivascular edema; (K-3)
kidney cells of rats treated with CCl4 and Sil showing slight vacuolation of epithelial lining renal tubules and endothelial lining glomerular
tuft; (K-4) (K-5) kidney cells of rats treated with CCl4 and 400 or 200 mg/kg total extract showing complete recovery of renal cells with no
histopathological changes; (K-6) kidney cells of rats treated with CCl4 and 200 mg/kg of the petroleum ether fraction showing no
histopathological changes; (K-7) kidney cells of rats treated with CCl4 and 100 mg/kg of the petroleum ether fraction showing slight
vaculations of epithelial lining of some renal tubules; (K-8) kidney cells of rats treated with CCl4 and 200 mg/kg of the chloroform fraction
showing no histopathological changes.
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As demonstrated in Table 6, the ethyl acetate fraction was able
to reduce the stable free radical DPPH, to yellow- colored
DPPH at low concentrations (50 and 100 lg/ml). The effect
was almost similar to that of the standard ascorbic acid. The
higher concentrations (500 and 1000 lg/ml) of the crude ex-
tract and chloroform fraction were able to reduce the DPPHO
H
H
H
O
1
1
3 5
9
10
11
14
16
18 22
20
2324
29 30
28
25
26
O
OH
HO
OH
OH
O
O
OH
OHHO
O
O
O
OH
6
OH
OH
1
4
5
8
1'
5'although the lower concentrations showed only weak
activity.Acknowledgments
The authors would like to thank Mr. Malik Saud at MAP-
PRC, College of Pharmacy, King Saud University for techni-
cal assistance and Mr. Anzarul Haque at the NMR Unit,R
2           R= H
3           R= OCH3
O O O
1
45
10
8
3'
2'
2
COOH
OH
OCH3
4
1
4
O O
5
COOH
O
OH
H
HO
H
H
H
HO H
OH
2'
3' 5
7
9
4 2
1"
3"
6"
10
470 S.I. Alqasoumi et al.College of Pharmacy, Salman Bin Abdulaziz University for
running NMR experiments.
References
Abdel-Hameed, E.S., 2009. Total phenolic contents and free radical
scavenging activity of certain Egyptian Ficus species leaf samples.
Food Chem. 114, 1271–1277.
Abdel-Kader, M.S., Alqasoumi, S.I., Hefnawy, M.M., AlSheikh,
A.M., 2010. Hepatoprotective effect and safety studies of Cleome
droserifolia. Alexandria. J. Pharm. Sci. 24, 13–21.
Abu-Mustafa, E.A., Fayez, M.B.E., 1967. Natural coumarins. VI.
Nuclear magnetic resonance spectra of some coumarin and
coumarilic acid derivatives. Can. J. Chem. 45, 325–327.
Adelman, R.D., Spangler, W.L., Beasom, F., Ishizaki, G., Conzelman,
G.M., 1981. Frusemide enhancement of neltimicin nephrotoxicity
in dogs. Journal of Antimicrobials and Chemotherapy 7, 431–
435.
Basudan, O.A., Ilyas, M., Parveen, M., Muhisen, H.M.H., Kumar, R.,
2005. A new chromone from Ficus lyrata. J. Asian Nat. Prod. Res.
7, 81–85.
Betti, J.L., 2004. An ethnobotanical study of medicinal plants among
the DJA biosphere reserve, cameroon. African Study Monogr. 25,
1–27.
Bilia, A.R., Ciampi, L., Mendez, J., Morelli, I., 1996. Phytochemical
investigations of Licania genus. ﬂavonoids from Licania pyrifolia.
Pharm. Acta Helv. 71, 199–204.
Brand, -W.W., Cuvelier, M.E., Berset, C., 1995. Use of free radical
method to evaluate antioxidant activity. Food Sci. Technol. 28, 25–
30.
Brenner, M.G., Stevens, C.W., 2006. Pharmacology, second ed.
Elsevier, New Delhi.
Brunton, L.L., Lazo, J.S., Parker, K.L., 2006. Goodman & Gilman’s
the Pharmacological Basis of Therapeutics, 11th ed. McGraw-Hill,
Medical Publishing Division, New York.
C¸aliskan, O., Polat, A.A., 2011. Phytochemical and antioxidant
properties of selected ﬁg (Ficus carica L.) accessions from the
eastern mediterranean region of Turkey. Sci. Hortic. 128, 473–478.
Chan, F.K.L., Leung, W.K., 2002. Peptic-ulcer disease. The Lancet.
360, 933–941.
Chang, M.-S., Yang, Y.-C., Kuo, Y.-C., Kuo, Y.-H., Chang, C., Chen,
C.-M., Lee, T.-H., 2005. Furocoumarin glycosides from the leaves
of Ficus ruﬁcaulis Merr. var. antaoensis. J. Nat. Prod. 68, 11–13.
Chunyan, C., Chunyan, C., BO, S., Ping, L., Jingmei, L., Ito, Y, 2009.
Isolation and puriﬁcation of psoralen and bergapten from Ficus
carica L. leaves by high-speed countercurrent chromatography. J.
Liq. Chromatogr. Relat. Technol. 32, 136–143.
Dacie, J.V., Lewis, S.M., 1968. Practical Haematology, fourth ed. J &
H Churchill, London.
Dat, N.T., Cai, X.F., Bae, K.-H., Kim, Y.H., 2002. Terpenoid
constituents from Youngia koidzumiana. Nat. Prod. Sci. 8, 55–57.
Del Rio, D., Stewart, A.J., Pellegrini, N., 2005. A review of recent
studies on malonaldehyde as toxic molecule and biological marker
of oxidative stress. Nutrition, Metabolism & Cardiovascular
Diseases 15, 316–328.
Edwards, C.R.W., Bouchier, I.A.D., 1991. Davidson’s Principles and
Practice Medicine. Churchill Livingstone Press, UK.
Esterbauer, H., Schaur, R.J., Zollner, H., 1991. Chemistry and
biochemistry of 4- hydroxynonenal, malonaldehyde and related
aldehydes. Free Radical Biology and Medicine 11, 81–128.
Farmer, E.E., Davoine, C., 2007. Reactive electrophile species.
Current Opinion in Plant Biology 10, 380–386.
Gonza`lez, A.G., Fraga, B.M., Gonza`lez, P., Hernandez, M.G.,
Ravelo, A.G., 1981. 13C NMR spectra of olean-18-ene derivatives.
Phytochemistry 20, 1919–1921.
Harrison, R.D., 2005. Figs and the diversity of tropical rainforests.
Bioscience 55, 1053–1064.Henry, R.J., Cannon, D.C., Winkelman, J.W., 1974. Clinical Chem-
istry, Principles and Techniques, second ed. Harper Row, New
York.
Hutchinson, J., Dalziel, J.M., Keay, R.W.J., 1958. Flora of West
Tropical Africa, second ed. Crown Agents, London.
Kitajima, J., Kimizuka, K., Tanaka, Y., 1999. New dammarane-type
acetylated triterpenoids and their related compounds of Ficus
pumila fruit. Chem. Pharm. Bull. 47, 1138–1140.
Kumar, M.R., Niyas, M.K., Mani, T.T., Rahiman, O.M.F., Kumar,
B.S., 2011. A review on medicinal plants for peptic ulcer. Der
Pharmacia Lettre. 3 (2), 180–186.
Kuo, Y.-H., Chaiang, Y.-M., 1999. Five new taraxastane-type
triterpenes from the aerial roots of Ficus microcarpa. Chem.
Pharm. Bull. 47, 498–500.
Kuo, Y.-H., Li, Y.-C., 1997. Constituent of the bark of Ficus
Microcarpa (L. f). J. Chin. Chem. Soc. 44, 321–325.
Lansky, E.P., Paavilainen, H.M., Pawlus, A.D., Newman, R.A., 2008.
Ficus spp. (ﬁg): Ethnobotany and potential as anticancer and anti-
inﬂammatory agents. J. Ethnopharmacol. 119, 195–213.
Li, Y.-C., Kuo, Y.-H., 1997. Two new isoﬂavones from the bark of
Ficus microcarpa. J. Nat. Prod. 60, 292–293.
Li, Y.-C., Kuo, Y.-H., 2000. Four new compounds, ﬁcusal, ﬁcuses-
quilignan a, b and ﬁcusolide diacetate from the heartwood of Fiucs
microcarpa. Chem. Pharm. Bull. 48, 1862–1865.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951.
Protein measurement with the folin-phenol reagent. J. Biol. Chem.
193, 265–275.
Migahed, A.M., 1996. Flora of Saudi Arabia, fourth ed. King Saud
University Press, Riyadh.
Murray, R.D.H., Mendez, J., Brown, S.A., 1982. The Natural
Coumarins, Occurrence, Chemistry and Biochemistry. Jhon Wiley
& Sons Ltd, Chichester, New York, Brisbane, Toronto, Singapore.
Navarro, V.J., Senior, J.R., 2006. Drug-related hepatotoxicity. New
England Journal of Medicine 35, 731–739.
Noumi, E., Fozi, F.L., 2003. Ethnomedical botany of epilepsy
treatment in fongo-tongo village, western province. Cameroon.
Pharm Biol. 41, 330–339.
O’Neil, M.J., 2001. The merck index: an encyclopedia of chemicals,
drugs and biologicals, 30th ed. Merck & CO., INC, Whitehouse
Station, NJ.
Penning-van Beest, F., Erkens, J., Petersen, K.U., Koelz, H.R.,
Herings, R., 2005. Main comedications associated with major
bleeding during anticoagulant therapy with coumarins. Eur. J.
Clin. Pharmacol. 61, 439–444.
Pocock, G., Richards, C.D., 2006. Human Physiology. The Basis of
Medicine, third ed. Oxford University Press.
Pouchert, C.J., Behnke, J., 1992. The Aldrich Library of 13C and 1H
FTNMR Spectra. Aldrich Chemical Co.
Prophet, E.P., Mills, B., Arrington, J.B., Sobin, L.H., 1994. Labora-
tory Methods in Histology, second ed. American Registry of
Pathology, Washington, D.C.
Qiao, C.-F., Han, Q.-B., Mo, S.-F., Song, J.-Z., Xu, L.-J., Chen, S.-L.,
Yang, D.-J., Kong, L.-D., Kung, H.-F., Xu, H.-X., 2006. Psora-
lenoside and isopsoralenoside, two new benzofuran glycosides from
Psoralea corylifolia. Chem. Pharm. Bull. 54, 714–716.
Robert, A., Nezamis, J.E., Lancaster, C., Davis, J.P., Field, S.O.,
Hanchar, A.J., 1983. Mild irritants prevent gastric necrosis through
‘‘adaptive cytoprotection’’ mediated by prostaglandins. Am. J.
Physiol. 245, G113–G121.
Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein-bound,
and nonprotein sulfhydryl groups in tissue with Ellman’s reagent.
Anal. Biochem. 25, 192205.
Sen, S., Chakraborty, R. DeB., Mazumder, J., 2009. Plants and
phytochemicals for peptic ulcer: An overview. Phcog. Rev. 3, 270–
279.
Utley, H.G., Bernheim, F., Hochstein, P., 1967. Effect of sulfhydryl
reagents on peroxidation in microsomes. Arch. Biochem. Biophys.
118, 29–32.
Phytochemical and pharmacological study of Ficus palmata growing in Saudi Arabia 471Varley, H., Alan, H.G., 1984. Tests in renal disease. In: Practical
Clinical Biochemistry, Vol. 1123. William Heinemann, Medical
Book Ltd London.Woolson, R.F., Clarke, W.R., 2002. Statistical Methods for the
Analysis of Biomedical Data, second ed. John Wiley & Sons. Inc.,
New York.
